The Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a Proposal
Establishing comparability of the originator and its biosimilar at the structural and functional level, by analyzing so-called quality attributes, is an important step in biosimilar development. The statistical assessment of quality attributes is currently in the focus of attention because both the FDA and the EMA are working on regulatory documents for advising companies on the use of statistical approaches for strengthening their comparability claim. In this paper, we first discuss “comparable” and “not comparable” settings and propose a shift away from the usual comparison of the mean values: we argue that two products can be considered comparable if the range of the originator fully covers the range of the biosimilar. We then introduce a novel statistical testing procedure (the “tail-test”) and compare the operating characteristics of the proposed approach with approaches currently used in practice. In contrast to the currently used approaches, we note that our proposed methodology is compatible with the proposed understanding of comparability and has, compared to other frequently applied range-based approaches, the advantage of being a formal statistical testing procedure which controls the patient’s risk and has reasonable large-sample properties.
KEY WORDSanalytical studies biosimilarity equivalence testing manufacturing change quality attributes
We are grateful to Muhanned Saeed and Matej Horvat for fruitful discussions. We thank the three reviewers for providing well-thought-out comments which greatly improved this manuscript.
We acknowledge the funding from the European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No 633567 and from the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 999754557.
Compliance with Ethical Standards
The opinions expressed and arguments employed herein do not necessarily reflect the official views of the Swiss Government.
- 2.FDA. Scientific considerations in demonstrating biosimilarity to a reference product. 2015. Available at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed 03 Feb 2017.
- 3.FDA. FDA withdraws draft guidance for industry: statistical approaches to evaluate analytical similarity. 2018. Available at https://www.fda.gov/Drugs/DrugSafety/ucm611398.htm. Accessed 17 July 2018.
- 10.Liao JJZ. Statistical methods for comparability studies, Cham: Springer International Publishing; 2016. p. 675–94.Google Scholar
- 11.CHMP. Reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development. 2017. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/03/WC500224995.pdf. Accessed 03 May 2018.
- 12.ICH. Pharmaceutical development Q8(R2). 2004. Available at https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf. Accessed 25 July 2018.
- 13.ICH. Validation of analytical procedures: text and methodology. 2015. Available at https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf. Accessed 03 May 2018.
- 15.ICH. Pharmaceutical quality systems. 2009. Available at https://www.fda.gov/downloads/drugs/guidances/ucm073517.pdf. Accessed 07 Sep 2018.
- 17.Chang W, Cheng J, Allaire J, Xie Y, McPherson J. Shiny: Web application framework for R. 2017. R package version 10.3.Google Scholar
- 18.R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2015.Google Scholar
- 19.Liao JJZ. Comparability studies: statistical considerations. CRC Press; 2018. p. 1–17.Google Scholar
- 22.Boulanger B. Assessment of analytical biosimilarity: the objective, the challenge, and the opportunities. 2017. Talk at ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. Slides available at https://www.efspi.org/Documents/Events/Regulatory%20Meetings/2016/5.2.Bruno%20Boulanger_EFSPI_talk_analytical_biosimilarity_13SEP2016_V3.pdf. Accessed 03 May 2018.
- 24.Surhone L, Timpledon M, Marseken S. Prediction interval. Betascript Publishing; 2010.Google Scholar